Publications by authors named "Jeff Wald"

Claim this Profile
D
Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease.
Aaron Koenig, Michael Lewis, Jeff Wald, Sigui Li, Mustafa Varoglu

Clin Transl Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAGE-217, A Novel GABA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies.
Ethan Hoffmann, George G Nomikos, Inder Kaul, Shane Raines, Jeff Wald

Clin Pharmacokinet· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
Amy Sturmer, Nozer Mehta, Jenna Giacchi, Tulin Cagatay, Roxanne Tavakkol, Jeff Wald

Clin Pharmacokinet· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man.
Ethan Hoffmann, Jeff Wald, Siva Lavu, John Roberts, Claire Beaumont

Br J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of netilmicin in short-term prophylactic treatment.
Nerea Jauregizar, Jeff A Wald, Ander Astobieta, Jose M Rodriguez Sasiain, John C Lukas

Br J Clin Pharmacol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis